Walid Khaled obtained his undergraduate degree in Genetics at the University of Edinburgh followed by a MSc at Imperial College, London working with Prof. Eric Lam on the PI3K pathway and cell cycle regulation. He did his PhD training with Prof. Christine Watson, Department of Pathology, University of Cambridge where he characterised the role of STAT6 in controlling mammary epithelial cell fate. In 2008 he was awarded a junior research fellowship at King's College, Cambridge and in 2009 he joined the Sanger Institute to work with Dr. Pentao Liu. During his time at Sanger he worked on the connection between cell fate regulation and breast cancer development particularly focusing on the transcription regulator BCL11A. In October 2013, he was appointed as a University Lecturer at the Department of Pharmacology, University of Cambridge. In May 2014 he was awarded a CRUK Career Establishment Award to investigate the cellular and molecular drivers of breast cancer heterogeneity with a particular focus on the development of novel therapies for triple negative breast cancer (TNBC).